Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

We are delighted to welcome Kristen and Nancy to our Board of Directors,” said Tom King, Executive Chairman of Achieve’s Board of Directors. “Their wealth of knowledge and experience in strategic ...

Enveda, a biotechnology company using AI to translate life's chemistry into new medicines, today announced the appointment of ...

Owkin also founded MOSAIC, the world's largest spatial multi-omics atlas for cancer research across nine cancer indications. Owkin has raised over $300 million through investments from leading ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with an alcohol) to be locked treasure chests of possibilities.

Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.